Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.62 |
| ▸ | CCR3 | P51677 | 18/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570615 | 0.94 | HRH1 (0.56) | HRH1CCR3KCNH2HRH3GPR119 | |
| SCHEMBL3282383 | 0.93 | GPR119 (0.59) | HRH1CCR3KCNH2HRH3GPR119 | |
| SCHEMBL5462103 | 0.89 | GPR119 (0.58) | HRH1CCR3KCNH2HRH3GPR119 | |
| SCHEMBL4719964 | 0.85 | GPR119 (0.67) | HRH1CCR3KCNH2HRH3GPR119 | |
| SCHEMBL4140781 | 0.84 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL20570284 | 0.84 | GPR119 (0.57) | HRH3GPR119 | |
| SCHEMBL4718927 | 0.84 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL20570922 | 0.83 | GPR119 (0.56) | HRH3GPR119 | |
| SCHEMBL214556 | 0.83 | GPR119 (0.56) | HRH3GPR119 | |
| SCHEMBL3091210 | 0.83 | GPR119 (0.64) | HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493743-B1 | Substituted bipiperidine intermediates and derivatives thereof | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-7276609-B2 | Process for preparing 4-(hydroxy)-[1,4′]bipiperidinyl-l'carboxylic acid tert-butyl ester | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7276609-B2 | Process for preparing 4-(hydroxy)-[1,4′]bipiperidinyl-l'carboxylic acid tert-butyl ester | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7276609-B2 | Process for preparing 4-(hydroxy)-[1,4′]bipiperidinyl-l'carboxylic acid tert-butyl ester | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1436280-B1 | A PROCESS FOR PREPARING 4-(HYDROXY)- 1,4']BIPIPERIDINYL-L'CARBOXYLIC ACID TERT-BUTYL ESTER | ASTRAZENECA AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| US-20040235895-A1 | Process for preparing 4-(hydroxy)-[1 4']bipiperidinyl-l'carboxylic acid tert-butyl ester | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| EP-1436280-A1 | A PROCESS FOR PREPARING 4-(HYDROXY)- 1,4']BIPIPERIDINYL-L'CARBOXYLIC ACID TERT-BUTYL ESTER | AstraZeneca AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2003031433-A1 | A PROCESS FOR PREPARING 4-(HYDROXY)-[1,4']BIPIPERIDINYL-L'CARBOXYLIC ACID TERT-BUTYL ESTER | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR1, CCR3, CCRL2 | HRH1 25/4885CCR3 2/4885KCNH2 1672/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20040235895-A1 | Process for preparing 4-(hydroxy)-[1 4']bipiperidinyl-l'carboxylic acid tert-butyl ester | HPD, HAMP, PAH | HRH1 14/4885CCR3 3364/4885KCNH2 865/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.